Premium
Controlled trial of ketanserin in hypertension.
Author(s) -
McGourty JC,
Silas JH,
Cowen KJ
Publication year - 1985
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1985.tb02795.x
Subject(s) - ketanserin , blood pressure , placebo , heart rate , sitting , medicine , antagonist , anesthesia , cardiology , diastole , receptor , serotonin , 5 ht receptor , alternative medicine , pathology
We have completed a double‐blind parallel group comparison of the 5‐HT2 receptor antagonist ketanserin with placebo in 22 hypertensive patients. Ketanserin (20‐40 mg twice daily) lowered sitting blood pressure more than placebo by 6.9 mm Hg systolic (NS), 13.1 mm Hg diastolic (P less than 0.05) and by 11.4 mm Hg mean arterial pressure (P less than 0.02). The fall in standing blood pressure was similar and we observed no first dose hypotensive effect. Ketanserin lowered the sitting heart rate by 11.1 beats/min (P less than 0.01). The drug was well tolerated.